JP2024536858A - Ｆｇｆｒ阻害剤及びその使用方法 - Google Patents

Ｆｇｆｒ阻害剤及びその使用方法 Download PDF

Info

Publication number
JP2024536858A
JP2024536858A JP2024518772A JP2024518772A JP2024536858A JP 2024536858 A JP2024536858 A JP 2024536858A JP 2024518772 A JP2024518772 A JP 2024518772A JP 2024518772 A JP2024518772 A JP 2024518772A JP 2024536858 A JP2024536858 A JP 2024536858A
Authority
JP
Japan
Prior art keywords
phenyl
amino
methyl
pyrrolo
triazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024518772A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024536858A5 (enExample
Inventor
ジンユー フー
シャンレイ フー
ヤンチャオ リュウ
ジーション チャン
ウェイボー チャン
シャオジン フー
ケヴィン エックス チェン
Original Assignee
３エイチ ファーマシューティカルズ カンパニー リミテッド
３エイチ （スージョウ） ファーマシューティカルズ カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ３エイチ ファーマシューティカルズ カンパニー リミテッド, ３エイチ （スージョウ） ファーマシューティカルズ カンパニー リミテッド filed Critical ３エイチ ファーマシューティカルズ カンパニー リミテッド
Publication of JP2024536858A publication Critical patent/JP2024536858A/ja
Publication of JP2024536858A5 publication Critical patent/JP2024536858A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024518772A 2021-09-23 2022-09-23 Ｆｇｆｒ阻害剤及びその使用方法 Pending JP2024536858A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021119861 2021-09-23
CNPCT/CN2021/119861 2021-09-23
CN2022096894 2022-06-02
CNPCT/CN2022/096894 2022-06-02
PCT/CN2022/121076 WO2023046117A1 (en) 2021-09-23 2022-09-23 Fgfr inhibitors and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024536858A true JP2024536858A (ja) 2024-10-08
JP2024536858A5 JP2024536858A5 (enExample) 2025-06-25

Family

ID=85720119

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024518772A Pending JP2024536858A (ja) 2021-09-23 2022-09-23 Ｆｇｆｒ阻害剤及びその使用方法

Country Status (8)

Country Link
US (1) US20240383905A1 (enExample)
EP (1) EP4405358A4 (enExample)
JP (1) JP2024536858A (enExample)
KR (1) KR20240075952A (enExample)
CN (1) CN118043327A (enExample)
AU (1) AU2022350571A1 (enExample)
CA (1) CA3231948A1 (enExample)
WO (1) WO2023046117A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117402161A (zh) * 2022-07-06 2024-01-16 上海科恩泰生物医药科技有限公司 一种具有fgfr抑制作用的亚砜亚胺类化合物、包含其的药物组合物及其用途
CN115232147B (zh) * 2022-08-09 2023-10-13 南方科技大学 一种作为HIF-2α激动剂的杂环衍生物
WO2024109799A1 (zh) * 2022-11-22 2024-05-30 西藏海思科制药有限公司 一种嘧啶衍生物及其在医药上的应用
WO2024208315A1 (zh) * 2023-04-07 2024-10-10 中国医药研究开发中心有限公司 芳香杂环类化合物及其制备方法和医药用途
EP4707277A1 (en) * 2023-05-04 2026-03-11 Daewoong Pharmaceutical Co., Ltd. Novel heterocyclic amine derivatives and pharmaceutical composition comprising same
WO2024245193A1 (zh) * 2023-05-26 2024-12-05 上海艾力斯医药科技股份有限公司 杂芳环类化合物、其药物组合物及其应用
KR20260115897A (ko) * 2023-11-17 2026-07-27 상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 질소 함유 헤테로아릴 유도체, 이의 제조 방법 및 의약학적 응용
WO2025149021A1 (zh) * 2024-01-10 2025-07-17 海思科医药集团股份有限公司 一种吡啶并吡咯衍生物及其在医药上的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061504A1 (en) * 2003-12-16 2005-07-07 Pfizer Products Inc. Bicyclic pyridazinone cannabinoid receptor ligands and uses thereof
JP2006527262A (ja) * 2003-06-09 2006-11-30 ファイザー・プロダクツ・インク カンナビノイド受容体リガンド及びその使用
JP2012506389A (ja) * 2008-10-23 2012-03-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング アザインドール誘導体
JP2018502159A (ja) * 2015-01-14 2018-01-25 湖北生物医薬産業技術研究院有限公司Ｈｕｂｅｉ Ｂｉｏ−Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｉｃａｌ Ｉｎｓｔｉｔｕｔｅ Ｉｎｃ． Ｂｔｋ阻害剤
CN108997380A (zh) * 2018-07-26 2018-12-14 长春海谱润斯科技有限公司 一种嘌呤化合物及其有机电致发光器件
JP2019519534A (ja) * 2016-05-24 2019-07-11 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズＳｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ 五員複素環［３，４−ｄ］ピリダジノン系化合物、その製造方法、医薬組成物及び応用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9808281A (pt) * 1997-03-19 2000-05-16 Basf Ag Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto
GB0031080D0 (en) * 2000-12-20 2001-01-31 Novartis Ag Organic compounds
ES3065954T3 (en) * 2019-05-13 2026-05-08 Relay Therapeutics Inc Fgfr inhibitors and methods of use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006527262A (ja) * 2003-06-09 2006-11-30 ファイザー・プロダクツ・インク カンナビノイド受容体リガンド及びその使用
WO2005061504A1 (en) * 2003-12-16 2005-07-07 Pfizer Products Inc. Bicyclic pyridazinone cannabinoid receptor ligands and uses thereof
JP2012506389A (ja) * 2008-10-23 2012-03-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング アザインドール誘導体
JP2018502159A (ja) * 2015-01-14 2018-01-25 湖北生物医薬産業技術研究院有限公司Ｈｕｂｅｉ Ｂｉｏ−Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｉｃａｌ Ｉｎｓｔｉｔｕｔｅ Ｉｎｃ． Ｂｔｋ阻害剤
JP2019519534A (ja) * 2016-05-24 2019-07-11 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズＳｈａｎｇｈａｉ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｍａｔｅｒｉａ Ｍｅｄｉｃａ， Ｃｈｉｎｅｓｅ Ａｃａｄｅｍｙ Ｏｆ Ｓｃｉｅｎｃｅｓ 五員複素環［３，４−ｄ］ピリダジノン系化合物、その製造方法、医薬組成物及び応用
CN108997380A (zh) * 2018-07-26 2018-12-14 长春海谱润斯科技有限公司 一种嘌呤化合物及其有机电致发光器件

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JONAS L., JOURNAL OF MEDICINAL CHEMISTRY, vol. 63(20), JPN6026011635, 2020, pages 11725 - 11755, ISSN: 0005835047 *
REGISTRY(STN)[ONLINE]、2010.09.27[検索日 2026.01.20] CAS登録番号 1242926-69-7、1242917-39-0, JPN7026001243, ISSN: 0005835048 *
XIAOWEI W., ACTA PHARMACEUTICA SINICA B, vol. 11(3), JPN6026011633, 2021, pages 781 - 794, ISSN: 0005835046 *
YULAN W., JOURNAL OF MEDICINAL CHEMISTRY, vol. 62(16), JPN6026011634, 2019, pages 7473 - 7488, ISSN: 0005835045 *

Also Published As

Publication number Publication date
CN118043327A (zh) 2024-05-14
EP4405358A1 (en) 2024-07-31
EP4405358A4 (en) 2025-12-24
US20240383905A1 (en) 2024-11-21
KR20240075952A (ko) 2024-05-30
CA3231948A1 (en) 2023-03-30
WO2023046117A1 (en) 2023-03-30
AU2022350571A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
JP5167291B2 (ja) ジヒドロピラゾロピリミジノン誘導体
WO2022174031A1 (en) Cdk inhibitors and methods of use thereof
CN103476767B (zh) 作为pi3激酶抑制剂的杂环化合物
CN101678014B (zh) 杂环激酶调节剂
CN101048406B (zh) 新型取代的咪唑衍生物
CN118043327A (zh) Fgfr抑制剂及其使用方法
WO2021121397A1 (zh) 取代的炔基杂环化合物
JP2021525783A (ja) Ｅｒｋ阻害剤及びその使用
EP3968999A1 (en) Fgfr inhibitors and methods of use thereof
CN112279852A (zh) 三唑并-嘧啶化合物和其用途
CA2740792A1 (en) Pyrazolopyrimidine jak inhibitor compounds and methods
JP2012511501A (ja) ジヒドロピリミドピリミジン誘導体
TW201326173A (zh) ５，７－經取代之－咪唑并［１，２－ｃ］嘧啶
HK40110493A (en) Fgfr inhibitors and methods of use thereof
HK40045058B (en) Triazolo-pyrimidine compounds and uses thereof
HK40027808B (en) Triazolo-pyrimidine compounds and uses thereof
HK40045058A (en) Triazolo-pyrimidine compounds and uses thereof
HK40027808A (en) Triazolo-pyrimidine compounds and uses thereof
HK1193090A (en) Heterocyclic compounds as pi3 kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250710

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20251021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251021

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260707